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Abstract. Ovarian cancer affects >295,000 women worldwide 
and is the most lethal of gynaecological malignancies. Often 
diagnosed at a late stage, current research efforts seek to 
further the molecular understanding of its aetiopathogenesis 
and the development of novel biomarkers. The present study 
investigated the expression levels of the glucogenic hormone 
asprosin [encoded by fibrillin‑1 (FBN1)], and its cognate 
receptor, olfactory receptor 4M1 (OR4M1), in ovarian cancer. 
A blend of in silico open access The Cancer Genome Atlas 
data, as well as in vitro reverse transcription‑quantitative PCR 
(RT‑qPCR), immunohistochemistry and immunofluorescence 
data were used. RT‑qPCR revealed expression levels of OR4M1 
and FBN1 in clinical samples and in ovarian cancer cell lines 
(SKOV‑3, PEO1, PEO4 and MDAH‑2774), as well as the 
normal human ovarian surface epithelial cell line (HOSEpiC) 
. Immunohistochemical staining of a tissue microarray was 
used to identify the expression levels of OR4M1 and asprosin 
in ovarian cancer samples of varying histological subtype and 
grade, including clear cell carcinoma, serous ovarian cancer 
and mucinous adenocarcinoma. Immunofluorescence analysis 
revealed asprosin expression in SKOV‑3 and HOSEpiC cells. 
These results demonstrated the expression of both asprosin 
and OR4M1 in normal and malignant human ovarian tissues. 
This research invokes further investigation to advance the 
understanding of the role of asprosin and OR4M1 within the 
ovarian tumour microenvironment.
Introduction
The tumour microenvironment has received growing interest 
owing to its role in metabolic dysregulation and tumorigenesis. 
Recent studies have associated dysregulation of extra cellular 
matrix (ECM) proteins, such as fibrillin‑1, with tumorigenesis. 
The structural glycoprotein, fibrillin‑1, is one of two cleavage 
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products encoded by the FBN1 gene (1). FBN1 encodes a 
66 exon proprotein known as profibrillin‑1, that is proteolyti‑
cally cleaved within the 65th exon at the consensus sequence 
X‑Arg‑X‑Lys/Arg‑Arg‑X by the enzyme furin (1,2). Cleavage 
produces the 320 kDa glycoprotein fibrillin‑1 and the recently 
discovered 30 kDa glucogenic hormone, asprosin (3).
Asprosin was recently identified by Romere et al (3) through 
an investigation of Neonatal Progeroid Syndrome (NPS); a 
disorder characterised by reduced insulin despite maintenance 
of euglycemia, extreme leanness and partial lipodystrophy (4). 
The pathogenesis of NPS is attributed to premature ablation 
of profibrillin‑1 as a result of a truncation mutation within the 
FBN1 gene (3). Investigation of NPS pathophysiology led to the 
classification of asprosin ‑ the c‑terminal cleavage product of 
profibrillin 1 ‑ as a novel orexigenic and glucogenic hormone, 
involved in the regulation of glucose homeostasis (3).
Elevated circulating levels of asprosin are present in 
patients with metabolic syndrome manifestations, such as 
insulin resistance and type 2 diabetes mellitus (T2DM), and 
are associated with obesity (5‑7). Adipose tissue is the primary 
source of asprosin secretion, with recent data showing that 
patients with cancer‑related anorexia exhibit significantly lower 
asprosin plasma levels compared to control counterparts (8,9). 
There is increasing evidence associating the expression of 
asprosin with metabolic disorders and complications during 
pregnancy, such as gestational diabetes, and preeclampsia, 
as well as intra‑uterine growth restriction (10). Additionally, 
elevated circulating asprosin levels have been noted in women 
with polycystic ovarian syndrome (PCOS), although further 
research is required to clarify the relevant role of obesity in 
this population (11).
Olfactory Receptor 743, an orphan G protein‑coupled 
receptor (GPCR), was recently identified as one of the possible 
receptors of asprosin in mice, whilst the human ortholog, 
olfactory receptor 4M1 (OR4M1), is considered to be the 
primary asprosin receptor in humans (12).
Detection of peripherally expressed olfactory recep‑
tors (ORs) is now well‑documented; despite initial beliefs for 
localised expression of these receptors solely within the olfac‑
tory epithelium of the nasal cavity (12). Existing data suggest 
that expression of OLFR734 (and its orthologue OR4M1) 
may involve the testis, whilst emerging evidence further 
indicates that expression may also extend to other reproduc‑
tive tissues, such as the ovaries, with further implications for 
fertility in mammals (13,14). Recent data present expression 
of this receptor in the ovaries of murine and bovine samples, 
supporting an auto/paracrine circuit between asprosin and 
OR4M1 which may be implicated in female fertility, as well 
as healthy ovarian follicular function (14). However, expres‑
sion of OR4M1 is yet to be explored in human tissues past the 
testis, with the exception of peripheral blood mononuclear cell 
expression in cases of traumatic brain injury (15).
Ovarian cancer is one of the most lethal gynaecological 
malignancies, affecting over 295,000 women worldwide (16). 
Dysregulation of FBN1 [which is expressed within the theca 
interna and stroma of healthy ovarian tissue (17)], in ovarian 
cancer, through Aurora A and BRCA 2 signalling, is asso‑
ciated with invasion and metastasis of tumour cells (18). 
Moreover, FBN1 is linked with worse overall survival, as well 
as advanced stage of disease in high grade serous ovarian 
cancer (19). However, studies have yet to investigate the 
expression of asprosin in reproductive tissues in both healthy 
women and those with ovarian cancer.
The regulation of glucose metabolism in ovarian cancer 
has been studied extensively, however, certain mechanisms 
are not fully elucidated. For example, hyperglycaemia drives 
ovarian tumour growth independently of insulin status (20). 
Of note, this heightened state of glucose metabolism is thought 
to accelerate tumour growth through increased aerobic 
glycolysis in what is known as the ‘Warburg effect’, and leads 
to a worse prognosis in cancer, including ovarian cancer (21). 
Increased expression of the glucose transporter GLUT‑1 in 
ovarian cancer is also linked to a decrease in overall survival, 
suggesting that glucose abundance is a rate limiting factor 
of glucose metabolism (22). In this context, investigating the 
expression of both FBN1 and the novel glucogenic hormone 
asprosin in human ovarian tissues will enhance our under‑
standing of the underlying molecular mechanisms implicated 
in ovarian cancer, as well as the regulation of its tumour 
microenvironment (20).
In this study ‑apart from the in silico FBN1 pan‑cancer 
expression‑ we provide novel evidence of the protein expres‑
sion of asprosin in ovarian cancer patients and healthy controls. 
We also demonstrate ‑to the best of our knowledge‑ for the first 
time expression of the olfactory receptor OR4M1 in the same 
tissues, raising the prospect of an auto/paracrine regulation at 
the ovarian level. Finally, we mapped the cellular distribution 
of asprosin in human ovarian cell lines, as well as the expres‑
sion of the cognate receptor OR4M1.
Materials and methods
Bioinformatics analysis. A Pancancer set of TCGA data was 
downloaded through cBioPortal (www.cbioportal.org) and 
Shiny Methylation Analysis Tool (SMART) (www.bioinfo‑zs.
com/smartapp/). Expression was validated through GEPIA 
(gepia.cancer‑pku.cn/) and GTeX (gtexportal.org/home/). 
Survival plots were obtained using Kaplan‑Meier Plotter 
[www.kmplot.com; (23)]. TCGA data sets are described under 
abbreviations.
Cell culture. SKOV‑3 (ECAAC 91091004), PEO1 
(ECAAC 10032308), PEO4 (ECAAC 10032309) and 
MDAH‑2774 (ATCC CRL‑10303) ovarian cancer cells were 
cultured using aseptic technique and incubated at 37˚C in humid‑
ified conditions at 5% CO2. Cells were regularly sub‑cultured 
at 80% confluency in T75 filter head flasks (Thermo Fisher 
Scientific, Inc.). SKOV‑3 and MDAH‑2774 were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher 
Scientific, Inc.). PEO1 and PEO4 were cultured in Roswell 
Park Memorial Institute (RPMI) (Thermo Fisher Scientific, 
Inc.). Media were supplemented with 10% foetal bovine 
serum (FBS) and 1% penicillin‑streptomycin (Thermo Fisher 
Scientific, Inc.). Normal ovarian epithelial cells, HOSEpiC 
(cat. no. 7310) were cultured in Poly‑L‑Lysine coated flasks 
(5 µg/ml) according to the protocol provided by the supplier 
(ScienCell), with Ovarian Epithelial Cell Medium (OEpICM) 
supplemented with 1% Ovarian Cell Growth Supplement 
and 1% penicillin‑streptomycin (ScienCell) and 10% FBS 
(Thermo Fisher Scientific, Inc.). For disassociation of adherent 
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cells, TrypLE express (Thermo Fisher Scientific, Inc.) was 
used. Cell count and viability were detected manually using 
a Neubauer Counting chamber with trypan blue (Invitrogen; 
Thermo Fisher Scientific, Inc.) exclusion method. SKOV‑3 
were derived from a human epithelial ovarian cancer patient 
and are haplo‑diploid adherent cells that carry a P53 muta‑
tion. PEO1 are derived from human ovarian adenocarcinoma. 
PEO4 were derived from the same patient as PEO1 although 
were harvested following treatment with platinum‑based 
chemotherapeutics and are cisplatin resistant. MDAH‑2774 
were derived from a patient with ovarian endometroid 
adenocarcinoma. The primary cell line, Human Ovarian 
Surface Epithelial cells (HOSEpiC), referred to as ovarian 
surface epithelial cells (OSE), were obtained commercially at 
passage 1 and are classified as normal ovarian epithelial cells.
Clinical ovarian samples. Clinical ovarian cancer samples 
(n=12, Table I) and samples from healthy volunteers (n=6, 
Table II) were obtained from patients at the First Department of 
Obstetrics and Gynaecology, ‘Papageorgiou’ General Hospital, 
Medical School, Aristotle University, Thessaloniki, Greece. 
Specimens from the 12 (average, 61.8 years; range, 48‑75) 
patients with ovarian cancer were taken during laparotomy 
for debunking surgery. Furthermore, in 6 reproductive‑age 
women (average, 41.7 years; range, 39‑45) without any ovarian 
pathology who had completed their reproductive cycle and 
underwent laparoscopic myomectomy for leiomyomas during 
the follicular phase of the cycle, an ovarian sample was taken. 
Institutional ethical approval was provided, and informed 
consent was obtained from each patient before the collection 
of samples (Reference: 14/11/STF/06).
Immunofluorescence. Cells were washed in phosphate buff‑
ered saline (PBS) solution (Thermo Fisher Scientific, Inc.), 
fixed with ice cold methanol, and washed three times with 
PBS. Samples were blocked with 5% bovine serum albumin 
(BSA) buffer (Thermo Fisher Scientific, Inc.), covered with 
parafilm, and left to incubate for 40 min at 37˚C. Asprosin 
(BioLegend) and OR4M1 (Novus Biologicals) primary 
antibodies (1:200/1:100 in 5% BSA) were added before 
incubation at 37˚C for 1 h (asprosin) or room temperature 
overnight (OR4M1). The coverslips were washed three times 
with PBS before the addition of secondary Alexa Flour 488 
antibody (Merck Millipore) at a concentration of 1:200. The 
samples were covered with parafilm and placed in a humidi‑
fied chamber for 30 min at room temperature, before being 
washed three times with PBS. Coverslips were transferred to a 
glass slide and sealed with a drop of Molecular ProbesProLong 
Diamond Antifade Mountant with DAPI (Thermo Fisher 
Scientific, Inc.) and clear nail varnish. The slides were then 
analysed, and images captured using a DM4000 microscope 
(Leica) lens at x100 magnification.
I m m u n o h i s t o c h e m i s t r y  o f  t i s s u e  m i c ro a r ra y. 
Paraffin‑embedded ovarian tissue microarray slides were 
purchased from US Biomax Inc. (cat. no. BC11115c). All 
tissue samples were collected under Health Insurance 
Portability and Accountability Act (HIPAA) approved proto‑
cols, following the appropriate ethical standards with the 
donors being fully informed and with their consent. Slides 
comprised of 100 biopsy cores of ovarian tissue: malignant 
and adjacent (Table SI). Slides were deparaffinised and rehy‑
drated, followed by antigen retrieval using sodium citrate 
solution (10 mM Sodium citrate in dH2O, 0.05% Tween‑20, 
pH 6.0). They were then washed in 0.025% Triton‑X in PBS 
(Thermo Fisher Scientific, Inc.) before a 15‑min incubation in 
3% H2O2 followed by additional washes in 0.025% Triton‑X in 
PBS. The slides were blocked with 5% BSA in PBS, followed 
by incubation with Asprosin/OR4M1 Antibody (1:200/1:100) 
overnight in a humidity chamber at 4˚C.
Slides were then washed three times in 0.025% Triton‑X 
in PBS and incubated with a secondary antibody in 
1% rabbit serum (ZytoChem Plus HRP‑DAB Kit, Zytomed 
Systems GmbH) for 1 h. The slides were then washed with 
0.025% Triton‑X in PBS to ensure the removal of unbound 
secondary antibody. Then streptavidin‑HRP conjugate was 
added to the bound secondary antibody and the slide incu‑
bated for a further 30 min within the humidity chamber. 
Slides were washed with PBS before the addition of DAB 
stain. These were then counterstained with haematoxylin and 
washed with 0.1% sodium bicarbonate. Finally, slides were 
dehydrated before the addition of DPX and coverslips, then 
left to dry overnight. Immunoreactivity was analysed using a 
light microscope (Zeiss GmbH). Results were calculated by 
Table I. Clinical details of patients with ovarian cancer.
Patient Histology Grade Stage Age, years
  1 Serous 3 IIIC 64
  2 Serous 3 IIIC 48
  3 Serous 3 IIIC 61
  4 Serous 2 IIIC 54
  5 Serous 3 IIIC 69
  6 Serous 3 IV 65
  7 Serous 3 IIIC 75
  8 Serous 3 IIIC 65
  9 Serous 3 IIIC 56
10 Serous 3 IIIC 64
11 Serous 3 IIIC 64
12 Serous 2 IIIC 56
Table II. Clinical details of the control group.
 Number of Mean diameter
 fibroids/ of fibroids/ Age, 
Patient patient patient, cm years
1 1   8.9 39
2 4   3.2 42
3 2   6.5 40
4 6   3.7 43
5 2   6.0 45
6 1 10.0 41
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two independent reviewers using a percentage score of positive 
tumour cells, as described previously (24).
RNA isolation, cDNA synthesis and reverse transcription‑quan‑
titative PCR (RT‑qPCR). Total RNA was extracted from cell 
lysates using the RNeasy Mini Kit (Qiagen, Inc.), before being 
reverse transcribed using a cDNA reverse transcription Kit 
(Applied Biosystems; Thermo Fisher Scientific, Inc.). Sample 
purity was assessed using Nano‑Drop 2000C (Thermo Fisher 
Scientific, Inc.) and relative gene expression measured using 
SYBR Green PCR Master Mix (Bio‑Rad) and qPCR with a 
Bio‑Rad CFX96 system according to the following conditions 
(Table III).
FBN1 primers were designed according to the Harvard 
Primer bank, whereas OR4M1 were generated according 
to a 2013 study (15). Additional primers include the house‑
keeping gene YWHAZ (Table IV). RQ values were calculated 
as previously described (24), according to the comparative 
2‑ΔΔCq analysis method (25).
Statistical analysis. Statistical analyses were performed 
using GraphPad prism9® software (GraphPad Software, Inc.). 
Error bars in graphs are presented as standard error of the 
mean (SEM). Mann Whitney U test and a one‑way ANOVA 
(Analysis of variance) with Tukey's multiple comparison post 
hoc statistical tests were applied to the observed measurements 
from the data. Variances in survival were generated using 
Kaplan‑Meier curves with log‑rank test. Beta values were 
calculated using the SMART methylation tool (SMART). The 
method for differential analysis conducted by GEPIA is listed 
as a one‑way ANOVA, where disease state (Tumour or Normal) 
is used as a variable for calculating differential expression: 
Gene expression against disease state. The expression data are 
first  log2(TPM+1) transformed for differential analysis and 
the log2FC is defined as median (Tumour) ‑ median (Normal). 
Genes with higher |log2FC| values and lower q values than 
pre‑set thresholds are considered differentially expressed 
genes. More information can be accessed at http://gepia.
cancer‑pku.cn/help.html. Unless stated otherwise, significance 
was set at P‑value <0.05.
Results
Expression of FBN1 in normal tissues. Initial analyses of 
FBN1 expression were conducted using publicly available 
data from The Genotype Tissue Expression (GTEX) project 
(Fig. 1). Fibroblasts, arteries, adipose tissue (subcutaneous 
and visceral) and the ovaries are amongst the tissues that 
express relatively high levels of FBN1, as do the studied 
female reproductive tissues. Brain and whole blood express 
the lowest FBN1 levels, along with the liver and pancreas 
(Fig. 1A). In the same dataset, we further analysed the 
co‑expression of FBN1 with the proteolytic enzyme furin, 
which may provide an oversight of potential furin‑mediated 
cleavage release of asprosin in these tissues (Fig. 1B). Furin 
is shown to exhibit ubiquitous expression throughout the 
human body with high levels detected across all tissues, 
including those with high FBN1 expression (e.g., normal 
human reproductive tissues, such as testis, vagina, uterus and 
ovaries).
Pancancer mapping of FBN1. We expanded our observa‑
tions by assessing the expression of FBN1 across 33 different 
cancer types using TCGA datasets through GEPIA. As 
presented in Fig. 2, significant differential regulation of 
FBN1 is noted for the following cancer types: bladder 
urothelial carcinoma (BLCA), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC), chol‑
angiocarcinoma (CHOL), lymphoid neoplasm diffuse large 
B‑cell lymphoma (DLBC), head neck and squamous cell 
carcinoma (HNSC), lung adenocarcinoma (LUAD), lung 
squamous cell carcinoma (LUSC), ovarian serous cystad‑
enocarcinoma (OV), pancreatic adenocarcinoma (PAAD), 
stomach adenocarcinoma (STAD), thyroid carcinoma 
(THCA), thymoma (THYM), uterine corpus endometrial 
carcinoma (UCEC), and uterine carcinosarcoma (UCS). 
Of the presented cancers, the female reproductive tissues: 
uterine, cervical, and ovarian exhibit lower FBN1 expression 
compared to corresponding normal tissues.
Table III. Bio‑Rad thermal cycling protocol for use with iTaq™ Universal SYBR‘ Green Supermix (Bio‑Rad Laboratories, Inc.).
Step Temperature, ˚C Time, sec Cycle
Activation 95 30   1
Denaturation 95   5 38
Amplification 60 30
Melt curve analysis 60 Increments of 5 Infinite
Table IV. List of primers utilized in the present study.







FBN1, fibrillin‑1; OR4M1, olfactory receptor 4M1; YWHAZ, 
tyrosine 3‑monooxygenase/tryptophan 5‑monooxygenase activation 
protein ζ.
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Given that the methylation status of FBN1 is of known 
biomarker potential (26), the FBN1 methylation status for the 
above cancers was assessed in the same dataset using SMART 
(Fig. S1). FBN1 methylation in colon adenocarcinoma (COAD) is 
significantly higher than healthy colon. Similar results are noted 
for breast (BRCA) and uterine endometrial carcinoma (UCEC). 
The methylation status of FBN1 within the ovarian cancer data 
set appears to be highly variable compared to other cancers, as 
indicated by the beta value of ~0.5; however, there is a lack of 
comparable normal data for ovarian cancer from TCGA.
Additional insight was sought through the analysis of 
FBN1 using cBioPortal. Mutations of FBN1 within the 
pancancer cohort of TCGA cancers appear to be most frequent 
in melanoma, uterine, stomach and colorectal cancer (Fig. 3A). 
A relatively lower frequency of alterations were detected in 
ovarian cancer samples compared to the other types of cancer, 
however, the high percentage of deep deletion within the cases 
presented must be noted.
Gain of function, shallow deletion and diploid appear to 
show the highest frequency of copy number variation within 
the samples (Fig. 3B). Six mutations on the FBN1 gene 
were identified in cases of serous ovarian cancer (Fig. 3C). 
Nonsense and splice‑site mutations (black and orange 
lollipops) give rise to a truncated FBN1‑encoded protein, 
whereas the four missense mutations (green lollipops) cause 
an amino acid substitution. Of note, one mutation has been 
Figure 1. Gene expression of FBN1 in normal tissues. (A) Expression levels of FBN1 in normal human tissues based on available data from The Genotype 
Tissue Expression project. (B) Co‑expression of FBN1 and furin, the enzyme which proteolytically cleaves profibrillin‑1 to fibrillin‑1 and asprosin, in normal 
human tissues. The different colours adjacent to furin and FBN1 denote the expression levels of both genes in (B). The darker the colour (dark blue) the higher 
the expression and the lighter (yellow) the lower the expression (indicated as TPM). The fine different coloured lines underneath the co‑expression data in (B) 
are used for identification purposes and relate to the different coloured violin plots in A. FBN1, fibrillin‑1; TPM, transcripts per million.
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identified in the asprosin coding region leading to a lysine to 
arginine (K2840R) substitution.
Expression of FBN1, asprosin and OR4M1 in ovarian cancer. 
We have validated the in‑silico data from TCGA and GTEX 
(Fig. 4A), using a smaller cohort of patients with ovarian 
cancer (n=12; stage III and IV). Our data corroborates the 
previous findings, as it demonstrates that the mRNA expres‑
sion of FBN1 was significantly lower in patients with ovarian 
cancer compared to healthy volunteers (n=6; Fig. 4B). In 
Figure 2. Pancancer profiling of FBN1 expression. Cancer types with significant differences compared with normal tissues (*P<0.01) are presented in the 
graphs [cancer (red) and normal (grey)]. Cancers with lower expression levels of FBN1 compared with normal samples included UCS, UCEC, THCA, OV, 
LUSC, LUAD, CESC and BLCA. Those with higher FBN1 expression levels included THYM, STAD, PAAD, HNSC, DLBC and CHOL. BLCA, bladder 
urothelial carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; DLBC, lymphoid neoplasm 
diffuse large b‑cell lymphoma; FBN1, fibrillin‑1; GEPIA, Gene Expression Profiling Interactive Analysis; HNSC, head and neck squamous cell carcinoma; 
LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; STAD, 
stomach adenocarcinoma; THCA, thyroid carcinoma; THYM, thymoma; TPM, transcripts per million; UCEC, uterine corpus endometrial carcinoma; UCS, 
uterine carcinosarcoma.
ONCOLOGY LETTERS  22:  650,  2021 7
Figure 3. Mutational profile of FBN1. (A) Pancancer overview of the frequency of FBN1 mutations. (B) Copy number of FBN1 alterations across all cancer 
types (as in Fig. 1A). (C) Location of FBN1 mutations, each lollipop represents an ovarian cancer patient and the corresponding location of the mutation within 
the gene (Ch15q21.1). Missense mutations are presented as green lollipops, nonsense mutations as black lollipops and splice as orange (source, cBioPortal). 
CNA, copy number alteration; GISTIC, Genomic Identification of Significant Targets in Cancer; FBN1, fibrillin‑1; VUS, variants of unknown significance; 
RSEM, RNA sequencing by expectation‑maximization.
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addition, OR4M1 expression was significantly up regulated 
in the same ovarian cancer samples (n=12) compared to the 
controls (n=6; Fig. 4C). We then measured expression of FBN1 
and OR4M1 in five ovarian cell lines: one normal ovarian 
epithelial cell line (HOSEpiC), and four ovarian cancer cell 
lines namely, SKOV‑3, PEO1, PEO4 and MDAH‑2774. FBN1 
was significantly over‑expressed in HOSEpiC cells compared 
to all studied ovarian cancer cell lines (Fig. 4D), whereas no 
apparent change in the expression of OR4M1 was noted across 
all five cell lines (Fig. 4E).
Since FBN1 is differentially regulated in ovarian cancer, its 
prognostic value was also assessed using Kaplan‑Meier plots 
for overall survival (OS) and progression free survival (PFS), 
Fig 5. Higher FBN1 expression was associated with poor OS 
and PFS, Fig. 5A and D, respectively. This predictive power 
of FBN1 appears to be significant for patients with late stage 
ovarian cancer (i.e., III and IV), rather than early stage (i.e., 
I and II), Fig. 5B and C and E and F for OS and PFS, respec‑
tively.
Immunohistochemical analysis of a tissue microarray 
containing 90 ovarian cancer cores and 10 normal adjacent 
tissue (NAT) cores, each representing a different clinical case, 
was used to measure the protein expression of asprosin and 
OR4M1 (Figs. 6 and 7). Asprosin was aberrantly expressed 
across all different histological subtypes (Fig. 6A), with no 
stage‑specific variation when samples were grouped to early 
(I and II) and late (III and IV) ovarian cancer stages (Fig. 6B). 
Examination of OR4M1 protein expression revealed similar 
non‑specific expression across different histological subtypes 
(Fig.7A). However, higher expression was detected in early 
(I and II) compared to late (III and IV) ovarian cancer stages 
(Fig. 7B).
Figure 4. Gene expression of FBN1 and OR4M1 at the ovarian level. (A) Expression data of FBN1 in OC from GEPIA for use as comparison. *P<0.05. 
Relative expression levels of FBN1 and OR4M1 in OC (red) and normal ovarian tissues (grey) were determined using reverse transcription‑quantitative PCR. 
(B) Significantly lower expression levels of FBN1 in OC samples (OC, n=12; stage III and IV) compared with FBN1 expression in normal ovarian tissue 
samples from healthy volunteers (n=6). **P<0.001 (samples obtained for the present study; different from the GEPIA cohort in A). (C) Significantly higher 
expression levels of OR4M1 in OC samples (OC, n=12; stage III and IV) compared with OR4M1 expression in normal ovarian tissue samples from healthy 
volunteers (n=6). ***P<0.0001. (D) Higher relative expression levels of FBN1 in normal ovarian surface epithelial cells (OSE), and lower expression levels in 
the studied human ovarian cancer cell lines (SKOV‑3, PEO1, PEO4 and MDAH‑2774). ***P<0.0001. (E) Lower relative expression levels of OR4M1 in normal 
ovarian epithelial cells, as well as in the PEO1 and MDAH‑2774 human ovarian cancer cell lines, compared with the relatively higher OR4M1 expression 
noted in SKOV‑3 and PEO4 cells. RQ indicates relative change in fold expression to the calibrator gene YWHAZ. FBN1, fibrillin‑1; GEPIA, Gene Expression 
Profiling Interactive Analysis; OC, ovarian cancer; OR4M1, olfactory receptor 4M1; OSE, HOSEpiC cells; TPM, transcripts per million; num(T), number of 
patients for tumour group; num(N), number of patients for normal group; RQ, relative quantity.
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Observations on the expression of asprosin and OR4M1 
were expanded using the SKOV‑3 ovarian cancer cell line, 
as well as the normal human ovarian epithelial cell line, 
HOSEpiC (OSE). Similarly, to the tissue sections, asprosin 
exhibited a cytoplasmic distribution (associated with struc‑
tures resembling microtubules or cytoskeleton), whereas 
OR4M1 appears to be expressed on the plasma membrane and 
cytoplasm in accordance with the expected distribution of a 
GPCR (Fig. 8).
Discussion
This study presents novel data regarding the expression of 
FBN1 (the gene encoding profibrillin‑1), asprosin (the novel 
orexigenic/glucogenic hormone which is cleaved from profi‑
brillin‑1), and OR4M1 (the human cognate receptor of asprosin) 
in cancer, focusing on ovarian cancer. Using an in‑silico 
approach, we demonstrate that FBN1 expression is ubiquitous 
in normal tissues, with high levels seen in fibrous tissues (e.g. in 
fibroblast cells) and arteries, in addition to female reproduc‑
tive tissues, such as the uterus and ovaries. Being the main 
source for the production of circulating asprosin (9), adipose 
tissue also exhibited high FBN1 expression. To date, asprosin 
production is thought to be specific to adipose tissue. However, 
the noted co‑expression of FBN1 with the proteolytic enzyme 
furin in human tissues is indicative of potential production and 
release of asprosin from other peripheral tissues, such as the 
ovaries.
Although multiple studies have shown FBN1 mutations 
as the cause of Marfan syndrome (MFS), which is further 
associated with increased risk of tumourigenesis (27), very 
little is known about the role of FBN1 mutations in cancer. 
Analysis of over one million cancer cases, including stomach, 
liver, oesophagus, prostate, gynaecological and other cancers, 
in a national cohort of patients with MFS in Taiwan showed 
a higher risk of developing cancer in these patients (27). Of 
note, the data presented from cBioportal in our study, indicate 
that six FBN1 mutations were present in patients with ovarian 
cancer, with one of the missense mutations located in the 
coding region for asprosin. Future GWAS studies are required 
to explore the potential involvement of these mutations in 
ovarian cancer.
The presented data from GEPIA in this study, show differ‑
ential FBN1 expression in 14 cancers, with higher expression 
noted in cancers of the stomach (STAD) and pancreas (PAAD). 
The latter is in line with previous research associating increased 
FBN1 expression in pancreatic islets with cellular progression 
from hyperplastic to angiogenic to insulinoma (28). Lower 
Figure 5. Kaplan‑Meier plots revealing the prognostic effects of FBN1 expression in OC. (A) OS in OC. (B) OS in early‑stage (I and II) OC. (C) OS in late‑stage 
(III and IV) OC. (D) PFS in OC. (E) PFS in early‑stage (I and II) OC. (F) PFS in late‑stage (III and IV) OC. FBN1, fibrillin‑1; HR, hazard ratio; OC, ovarian 
cancer; OS, overall survival; PFS, progression‑free survival.
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FBN1 expression, however, was noted in cancers that origi‑
nate from fibrous tissues, including gynaecological cancers, 
such as cervical (CESC), endometrial (UCEC), uterine (UCS) 
and ovarian (OV) cancers. The downregulation of FBN1 in 
this cohort of cancers may be suggestive of tissue‑specific 
expression compared to up‑regulation in other malignan‑
cies. Based on a previous study, FBN1 has a single CpG‑rich 
dominant promoter that is highly conserved in mammals (29). 
Interestingly, a study showed that gene expression and activity 
of the promoter was significantly higher in MG63 cells (a 
Figure 6. Ovarian tissue microarray, including 90 ovarian cancer cores, stained with asprosin antibody (1:200). Corresponding values for scoring: 0, <10%; 
1, 10‑25%; 2, 26‑50%; 3, 51‑75%; and 4, >76% of cells stained. (A) Asprosin staining by histological subtype/grade: LGSC, HGSC, MAC, EAC and CCC. 
(B) Asprosin staining of early (I and II) and late (III and IV) ovarian cancer stages, revealing no significant difference. (C) HGSC, stage II at x5 (left) 
and x20 (right) magnification. (D) HGSC, stage I at x5 (left) and x20 (right) magnification. (E) HGSC, stage III at x5 (left) and x20 (right) magnification. 
CCC, clear cell carcinoma; EAC, endometroid adenocarcinoma; HGSC, high grade serous carcinoma; LGSC, low grade serous carcinoma; MAC, mucinous 
adenocarcinoma.
Figure 7. Immunohistochemical staining of an ovarian tissue microarray, including 90 ovarian cancer cores, with OR4M1 antibody (1:100). (A) OR4M1 
staining by histological subtype/grade: LGSC, HGSC, MAC, EAC and CCC. (B) Higher OR4M1 staining in early (I and II) compared with late (III and IV) 
ovarian cancer stages. *P=0.04. (C) HGSC, stage II at x5 (left) and x20 (right) magnification. (D) HGSC, stage I at x5 (left) and x20 (right) magnification. 
(E) HGSC, stage III at x5 (left) and x20 (right) magnification. CCC, clear cell carcinoma; EAC, endometroid adenocarcinoma; HGSC, high grade serous 
carcinoma; LGSC, low grade serous carcinoma; MAC, mucinous adenocarcinoma; NAT, normal adjacent tissue; OR4M1, olfactory receptor 4M1.
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human osteosarcoma line) when compared to MDA‑MB‑231 
cells (a breast cancer cell line) (29). This agrees with previous 
observations that variations in the activity of the promoter 
region can exert a heritable transcriptional effect (30,31). As 
such, this might also explain, at least in part, the varying 
expression of FBN1 among different cancer types. Indeed, 
transcription factor binding motifs identified in the promoter 
region of FBN1, subserve tissue‑specific functions (29). Of 
note, furin expression is slightly elevated in ovarian cancer 
compared to controls (data not shown). Therefore, in terms 
of the secretion of the cleaved peptide asprosin, the dynamics 
may be different. Moreover, it is possible that FBN1/asprosin 
may exert different effects in health and disease. For example, 
in the normal ovary, it might affect steroidogenesis and in the 
cancerous tissue may be implicated in the Warburg effect. 
Especially the later, warrants further investigation given that 
asprosin is a glucogenic peptide, that stimulates the release 
of glucose from hepatic cells. It is well known that in cancer 
cells, there is dramatic increase of the rate of glucose uptake 
and subsequent lactate production (32). Recently, inhibition of 
Bcl2 in SKOV3 ovarian cancer cells, appeared to reverse the 
Warburg effect and promoted oxidative stress‑induced apop‑
tosis in vitro (33). Further studies are needed to investigate the 
clinical application of asprosin as a potential mediator of the 
Warburg effect in ovarian cancer.
Furthermore, changes in the methylation status of FBN1 
have shown biomarker value. For example, hypermethylation 
of Synuclein Alpha (SNCA) and FBN1 in stool samples show 
excellent sensitivity and specificity for colon cancer (34). 
Additional data has shown similar potential for colorectal 
cancer (26). The data presented in our study support these find‑
ings as methylation of FBN1 is significantly higher in colon 
adenocarcinoma (COAD) compared to healthy colon. Similar 
results are seen for breast (BRCA) and uterine endometrial 
carcinoma (UCEC). Methylation of FBN1 in normal ovarian 
tissue requires further investigation, since there is a lack of 
comparable normal methylation data held through TCGA and 
SMART for ovarian cancer.
In silico data for ovarian cancer were further validated 
using clinical ovarian tissue samples from patients with 
stage III/IV ovarian cancer, as well as both cancer and normal 
human ovarian epithelial cell lines Our present findings show 
significantly downregulated FBN1 expression in the ovarian 
cancer samples compared to those from healthy controls, 
in accord with the data noted in GEPIA. Moreover, FBN1 
expression was detected in the human ovarian cancer cell line 
SKOV‑3, the high‑grade serous PEO1 and PEO4 cell lines, and 
the human endometroid ovarian cancer cell line MDAH‑2774, 
as well as the normal ovarian epithelial cells (OSE). As noted 
in the clinical ovarian cancer samples, these human ovarian 
cancer cell lines exhibit relatively lower FBN1 expression 
compared with the normal ovarian tissue.
The differential ‑ albeit not‑significant ‑ expression of 
FBN1 in the BRCA2 mutant and silent (wild‑type) PEO1 
Figure 8. Immunofluorescence imaging of OSE normal human ovarian epithelial cells and SKOV‑3 human serous ovarian cancer cells, with DAPI nuclear 
staining (red) and with ASP and OR4M1 (green). Magnification, x100 using a Leica DM4000 microscope (Scale bar, 10 µm). ASP, asprosin; OR4M1, olfactory 
receptor 4M1.
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and PEO4 cell lines, respectively, is of interest given that the 
tumour suppressor gene BRCA2 is an inhibitor of FBN1 (18). 
BRCA2 inhibition of FBN1 is associated with the inhibition of 
matrix metalloproteases (MMPs), including MMP2, MMP9 
and MMP13, as well as the activation of cellular adhesion 
molecules which protect against metastasis (18). However, 
it should be noted that database analyses on survival times 
are often biased because of limited clinical information. 
These should be validated ideally with prospective cohorts 
employing sophisticated statistical considerations. Due to the 
nature of this study, such advanced statistical considerations 
were not feasible, thus this should be acknowledged as a limi‑
tation of the present study. The prognostic value of FBN1 in 
cancer is continually evolving (19,35,36). In our study, high 
FBN1 expression predicts lower overall‑ and progression‑free 
survival of patients with late stages (i.e., III and IV) of 
ovarian cancer, corroborating previous findings which show 
promising prognostic potential of FBN1 as part of a panel of 
genes (19,35). Similarly, elevated FBN1 expression in both 
colon and bladder cancer are associated with worse overall 
survival (19,37,38).
Interestingly, previous data suggest that glucose metabo‑
lism including hyperglycaemia in ovarian cancer is associated 
with tumour growth and progression as well as worse survival 
outcome (20,39). As such, further research is required to 
elucidate the potential role of the glucogenic hormone and 
product of FBN1, asprosin, at the level of the ovaries. To that 
aim and following studies on the expression in normal murine 
and bovine ovaries (13,14), we provide novel data regarding the 
expression of both asprosin and its cognate receptor, OR4M1, 
in normal human ovaries and ovarian cancer.
Using immunohistochemical staining, we show aberrant 
protein expression of asprosin in ovarian cancer samples and 
normal adjacent tissue. In routine examination, normal adjacent 
tissue is often taken from the vicinity (<2 cm) of malignant cells 
and is frequently used as a control for cancer studies. Of note, 
recent transcriptome profiling data comparing normal adjacent 
tissue samples to healthy control tissue ‑ which is removed 
from a substantial distance away from the primary tumour or 
from an age matched healthy control ‑ suggest that there is 
premalignant conditioning of normal adjacent tissue (40). In 
the present study no apparent differences in asprosin protein 
expression were observed amongst different histological 
subtypes or stages of ovarian cancer, with staining represen‑
tative of high asprosin expression in most cases (cancer and 
normal adjacent tissue samples). Similar widespread protein 
expression of asprosin was recently documented in malignant 
mesothelioma (41).
In our cell lines, this cytoplasmic distribution appeared 
associated with structures resembling microtubules or cyto‑
skeleton. As this is a secreted protein, one would expect to 
observe a pattern that resembles the endoplasmic reticulum, or 
the Golgi, or even a vesicular pattern. One possibility is that 
asprosin production by furin‑mediated cleavage, escapes the 
conventional secretory route, and follows a non‑conventional 
secretory pathway that may not be dependent on vesicular 
exocytosis. Future in vitro studies using specific markers of 
cytoplasmic organelles should address this finding. One of 
the limitations of this study is the inability to measure mRNA 
expression for asprosin, as this is a cleaved peptide therefore 
only protein and precursor FBN1 mRNA expression can be 
measured. The fact that FBN1 colocalises with furin in the 
ovary, favours local production of the cleaved product. Future 
studies should include the measure of asprosin levels from 
conditioned media of ovarian cell lines and/or ovarian explants 
to elucidate the secretion rate of asprosin from this tissue.
Moreover, given that asprosin binds to a GPCR, it is 
expected to have a discrepancy between mRNA and protein 
levels. It is possible after prolonged exposure to the ligand (i.e. 
asprosin), OR4M1 might undergo desensitisation, as a mecha‑
nism limiting GPCR signalling and subsequent activation of 
adenylyl cyclase. In doing so, OR4M1 can be detected in the 
cytoplasm (rather the cytoplasmic membrane) as a process of 
internalisation, or in lesser amounts if it undergoes lysosomal 
degradation rather than recycling (42). Future studies should 
concentrate on activation of second messengers in vitro. It 
is known that GPCRs are capable of activating multiple G 
proteins (43), therefore it is important to measure release of 
cAMP, or IP3 and activation of PKA or PKC in vitro. It has 
also been shown that asprosin is capable of binding to Toll‑like 
receptor 4 (TLR4) and activating JNK mediated‑pathway in 
pancreatic β‑cells (44). Of note, the role of TLR4 in ovarian 
cancer is well documented (45), and future studies should also 
investigate the possibility of asprosin binding to TLR4 as well 
in ovarian cells.
We acknowledge that there are certain additional limita‑
tions in this study. The validation of the in silico data is 
performed on a small number of clinical samples and controls. 
Moreover, the samples of ovarian cancer where RT‑qPCR 
was performed were all stage III/IV, as such we do not 
have the data to compare mRNA expression of FBN1 and 
OR4M1 in early stages of ovarian cancer. In silico analysis 
(Ualcan; http://ualcan.path.uab.edu) indicated that FBN1 is 
overexpressed across all stages with significantly increased 
expression when comparing stages II vs. III and II vs IV (data 
not shown). In addition, we demonstrate protein expression of 
asprosin in clinical samples and cells, however the study does 
not examine whether the ovaries are capable of secreting this 
peptide, since this was beyond the scope of the present paper. 
Future experiments using conditioned media from ovarian cell 
lines and/or ovarian explants are planned which will enable us 
to answer this question.
In conclusion, to the best of our knowledge, this is the first 
study to demonstrate expression of asprosin and its cognate 
receptor, OR4M1, in the human ovaries in health and cancer, 
focusing specifically on ovarian cancer. The presence of 
the recently identified orexigenic and glucogenic hormone 
asprosin (the cleaved product of profibrillin‑1) in the human 
ovaries suggests a specific endocrine and/or auto/paracrine 
role for asprosin in human female reproduction. Indeed, the 
novel findings of the present study open two distinct lines 
of investigation: the potential role and effects of asprosin in 
normal ovaries in terms of fertility and steroidogenesis; as 
well as the potential involvement of asprosin as a gluconeo‑
genic peptide in cancer. The latter is of particular importance 
given that hyperglycaemia is a contributing factor to the onset 
and progression of epithelial ovarian cancer (20). However, it 
should be noted that the exact role of asprosin and its receptor 
in the pathogenesis of ovarian cancer and its precise clinical 
relevance remains to be clarified. Further research is required 
ONCOLOGY LETTERS  22:  650,  2021 13
to expand on the present findings and elucidate the potential 
role of asprosin in health and disease using in vitro and in vivo 
models, as well as larger cohorts of patients undergoing treat‑
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